Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib for gynecological malignancies
ChiCTR2000040225Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Gynecological neoplasia, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Gynecological neoplasia
Beyond the preview
Go deeper on ChiCTR2000040225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040225.